Could thiazolidinediones increase the risk of heart failure in Friedreich's ataxia patients?

Movement Disorders

Volumn 26, Issue 5, 2011, Pages 769-771

  García Giménez, José L ^a,b   Sanchis Gomar, Fabián ^b   Pallardó, Federico V ^a,b  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Heart failure; Pioglitazone; Rare disease; Rosiglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLOOXYGENASE 2; FRATAXIN; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; ROSIGLITAZONE;

ARTICLE; BIOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FRIEDREICH ATAXIA; HEART FAILURE; HEART MUSCLE; HUMAN; INCIDENCE; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS; TREATMENT RESPONSE;

ANIMALS; FRIEDREICH ATAXIA; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, BIOLOGICAL; PPAR GAMMA; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 79955118177     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23711     Document Type: Article

References (19)

1. Rosen CJ. Revisiting the rosiglitazone story-lessons learned. N Engl J Med. 2010; 363: 803-806.
2. Mitka M. Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues. JAMA. 2010; 303: 2341-2342.
3. Woodcock J SJ, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Eng J Med. 2010; 363: 1489-1491.
4. Wu AH. Cardiotoxic drugs: clinical monitoring and decision making. Heart. 2008; 94: 1503-1509.
5. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 2006; 27: 728-735.
6. Russell LK, Mansfield CM, Lehman JJ, et al. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res. 2004; 94: 525-533.
7. Metzler M. Diverse effects in Friedreich's ataxia place PGC-1alpha center-stage. Clin Genet. 2009; 76: 345-347.
8. Marmolino D, Manto M, Acquaviva F, et al. PGC-1alpha down-regulation affects the antioxidant response in Friedreich's ataxia. PLoS One. 2010; 5: e10025.
9. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996; 271: 1423-1427.
10. Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med. 1996; 335: 1169-1175.
11. Child JS, Perloff JK, Bach PM, Wolfe AD, Perlman S, Kark RA. Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients. J Am Coll Cardiol. 1986; 7: 1370-1378.
12. Marmolino D, Acquaviva F, Pinelli M, et al. PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich's ataxia therapy. Cerebellum. 2009; 8: 98-103.
13. Coppola G, Marmolino D, Lu D, et al. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia. Hum Mol Genet. 2009; 18: 2452-2461.
14. Purkiss P, Baraitser M, Borud O, Chalmers RA. Biochemical and clinical studies of Friedreich's ataxia. J Neurol Neurosurg Psychiatry. 1981; 44: 574-582.
15. Ensuring drug safety: lessons from the thiazolidinediones. Lancet. 2007; 370: 1101.
16. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Effect of aspirin use on thiazolidinediones and cardiovascular events. JAMA. 2008; 299: 1539; author reply 1539-1540.
17. Stoessl AJ. Movement disorders: new insights into Parkinson's disease. Lancet Neurol. 2011; 10: 5-7.
18. Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GV. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J Biol Chem. 2008; 283: 25628-25637.
19. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol. 2011; 68: 45-50.